- Visibility 209 Views
- Downloads 208 Downloads
- Permissions
- DOI 10.18231/j.ijmr.11710.1768021632
-
CrossMark
Unveiling the menace: a case series of fungal meningitis with galactomannan and beta-D-glucan detection and the efficacy of amphotericin B and flucytosine treatment
- Author Details:
-
Rachana Patel
-
Bhavinkumar Bhagubhai Patel
-
Trupti Jansari
-
Amit Pravin Chauhan
-
Tanuja Javadekar
Rachana Patel
Bhavinkumar Bhagubhai Patel
Trupti Jansari
Amit Pravin Chauhan
Fungal meningitis is a rare but serious infection of the central nervous system with high morbidity and mortality, especially when diagnosis is delayed. Standard CSF analysis often fails to identify the aetiology, making early detection challenging. This case series explores the utility of CSF fungal biomarkers—galactomannan and beta-D-glucan—in diagnosing fungal meningitis and the clinical outcomes following prompt antifungal therapy.
We describe three critically ill adult patients diagnosed with fungal meningitis of varying aetiologies. All cases had initial negative routine CSF studies, cultures, and Bio Fire panels. Diagnosis was confirmed using elevated CSF galactomannan and beta-D-glucan levels. Each patient was treated with liposomal amphotericin B and flucytosine, followed by step-down therapy with voriconazole. All patients showed neurological recovery without residual deficits and were successfully discharged after prolonged ICU care.
This series underscores the diagnostic challenges posed by fungal meningitis and the pivotal role of adjunctive CSF biomarkers in early detection. The use of galactomannan and beta-D-glucan assays significantly enhanced diagnostic sensitivity in our patients. Early initiation of appropriate antifungal therapy based on these biomarkers contributed to favourable outcomes.
CSF galactomannan and beta-D-glucan are valuable diagnostic tools for fungal meningitis, especially in cases with negative conventional workups. Timely diagnosis and antifungal therapy with amphotericin B and flucytosine can lead to full neurological recovery, even in critically ill patients.
References
- Elsawy A, Almaghrabi R, Elsaid T, Alshehri M, Almaghrabi A. Aspergillus terreus meningitis in immunocompetent patient: a case report. Front Microbiol. 2015;6:1353.
- Pettit AC, Kropski JA, Castilho JL, Schmitz JE, Rauch CA, Mobley BC, et al. The index case for the fungal meningitis outbreak in the United States. N Engl J Med. 2012;367(22):2119–25.
- Chong GM, Maertens JA, Lagrou K, Driessen GJ, Cornelissen JJ, Rijnders BJ. Diagnostic performance of galactomannan antigen testing in cerebrospinal fluid. J Clin Microbiol. 2016;54(2):428–31.
- Malani AN, Singal B, Al Sous O, Summons TA, Durkin MM, Pettit AC. (1,3)-β-d-glucan in cerebrospinal fluid for diagnosis of fungal meningitis associated with contaminated methylprednisolone injections. J Clin Microbiol. 2015;53(3):799–803.
- Rathish B, Wilson A, Warrier A, Pillay R, Thomas J. Aspergillus fumigatus meningitis in an immunocompetent young woman. Indian J Pathol Microbiol. 2020;63(3):488–90.
- Desai SD, Seth S, Shah A, Vaishnav B. Aspergillus meningoencephalitis in a patient with human immunodeficiency virus infection: normal cerebrospinal fluid does not mean absence of meningitis. Indian J Sex Transm Dis AIDS. 2016;37(2):185–9.
- Hiraga A, Aoki R, Nakamura KI, Kuwabara S. Rapidly progressive Aspergillus meningitis successfully treated with voriconazole and corticosteroids. Neurol Sci. 2018;39:577–9.
- Forster J, Hoenigl M, Suerbaum S, Wagener J, Dichtl K. Serologic biomarkers in Candida and Aspergillus infections of the central nervous system: A comparison of galactomannan, mannan and β- 1,3-D-gucan testing from serum and cerebrospinal fluid. Mycoses. 2022;65(7):709–14.
- Tang HJ, Liu WL, Chang TC, Li MC, Ko WC, Wu CJ, et al. Multiple brain abscesses due to Aspergillus fumigatus in a patient with liver cirrhosis: a case report. Medicine (Baltimore). 2016;95(9):e2813.
- Memória Jr JR, Lopes Rufino EP, do Rêgo Aquino PL, Vaz Guimarães Filho F, Maranhão Neto T, de Vasconcelos HKNB. Brain aspergilloma in an immunocompetent individual: a case report. Surg Neurol Int. 2020;11:211.
- Shariati A, Didehdar M, Rajaeih S, Moradabadi A, Ghorbani M, Falahati V, et al. Aspergillosis of central nervous system in patients with leukemia and stem cell transplantation: a systematic review of case reports. Ann Clin Microbiol Antimicrob. 2021;20(1):44. 428 Patel et al. / Indian Journal of Microbiology Research 2025;12(3):423–428
- Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al.; Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.
- Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscoll T, Cornely OA, et al. Improved outcome in central nervous system aspergillosis, using voriconazole treatment. Blood. 2005;106(8):2641–5.
- Kourkoumpetis TK, Desalermos A, Muhammed M, Mylonakis E. Central nervous system aspergillosis: a series of 14 cases from a general hospital and review of 123 cases from the literature. Medicine (Baltimore). 2012;91(6):328–36.
- Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2010;50(3):291–322.